Anti-SSR3 monoclonal antibody

Pre-made anti-SSR3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SSR3/SSR3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1826-Ab-1/ GM-Tg-hg-IP1826-Ab-2Anti-Human SSR3 monoclonal antibodyHuman
GM-Tg-rg-IP1826-Ab-1/ GM-Tg-rg-IP1826-Ab-2Anti-Rat SSR3 monoclonal antibodyRat
GM-Tg-mg-IP1826-Ab-1/ GM-Tg-mg-IP1826-Ab-2Anti-Mouse SSR3 monoclonal antibodyMouse
GM-Tg-cynog-IP1826-Ab-1/ GM-Tg-cynog-IP1826-Ab-2Anti-Cynomolgus/ Rhesus macaque SSR3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1826-Ab-1/ GM-Tg-felg-IP1826-Ab-2Anti-Feline SSR3 monoclonal antibodyFeline
GM-Tg-cang-IP1826-Ab-1/ GM-Tg-cang-IP1826-Ab-2Anti-Canine SSR3 monoclonal antibodyCanine
GM-Tg-bovg-IP1826-Ab-1/ GM-Tg-bovg-IP1826-Ab-2Anti-Bovine SSR3 monoclonal antibodyBovine
GM-Tg-equg-IP1826-Ab-1/ GM-Tg-equg-IP1826-Ab-2Anti-Equine SSR3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1826-Ab-1/ GM-Tg-hg-IP1826-Ab-2; GM-Tg-rg-IP1826-Ab-1/ GM-Tg-rg-IP1826-Ab-2;
GM-Tg-mg-IP1826-Ab-1/ GM-Tg-mg-IP1826-Ab-2; GM-Tg-cynog-IP1826-Ab-1/ GM-Tg-cynog-IP1826-Ab-2;
GM-Tg-felg-IP1826-Ab-1/ GM-Tg-felg-IP1826-Ab-2; GM-Tg-cang-IP1826-Ab-1/ GM-Tg-cang-IP1826-Ab-2;
GM-Tg-bovg-IP1826-Ab-1/ GM-Tg-bovg-IP1826-Ab-2; GM-Tg-equg-IP1826-Ab-1/ GM-Tg-equg-IP1826-Ab-2
Products NameAnti-SSR3 monoclonal antibody
Formatmab
Target NameSSR3
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SSR3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1826-Ag-1Recombinant multi-species SSRG/ SSR3/ TRAPG protein


    Target information

    Target IDGM-IP1826
    Target NameSSR3
    Gene ID6747,67437,81784,706518,477124,101085915,767980,100057287
    Gene Symbol and Synonyms0610038P07Rik,SSR3,TRAPG
    Uniprot AccessionQ9UNL2,Q08013,Q3SZ87
    Uniprot Entry NameSSRG_HUMAN,SSRG_RAT,SSRG_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000114850
    Target ClassificationN/A

    The target: SSR3, gene name: SSR3, also named as TRAPG. The signal sequence receptor (SSR) is a glycosylated endoplasmic reticulum (ER) membrane receptor associated with protein translocation across the ER membrane. The SSR is comprised of four membrane proteins/subunits: alpha, beta, gamma, and delta. The first two are glycosylated subunits and the latter two are non-glycosylated subunits. This gene encodes the gamma subunit, which is predicted to span the membrane four times. [provided by RefSeq, Aug 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.